NASDAQ: COLLCollegium Pharmaceutical Inc Stock
$37.03+1.16 (+3.23%)
Updated Jul 2, 2026
COLL Price
$37.03
Fair Value Price
N/A
Market Cap
$1.20B
52 Week Low
$29.19
52 Week High
$50.79
P/E
15.69x
P/B
3.84x
P/S
1.33x
PEG
0.36x
Dividend Yield
N/A
Revenue
$796.33M
Earnings
$74.95M
Gross Margin
60.7%
Operating Margin
23.31%
Profit Margin
9.4%
Debt to Equity
4.29
Operating Cash Flow
$331M
Beta
0.58
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
COLL Overview
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine COLL's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +28.50% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
COLL
Ranked#7 of 51
Ranked#7 of 51
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $174.26 | A | |
| $39.80 | A | |
| $4.33 | A |
Be the first to know about important COLL news, forecast changes, insider trades & much more!
COLL News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how COLL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
COLL ($37.03) is trading below its intrinsic value of $47.10, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
COLL is poor value based on its earnings relative to its share price (15.69x), compared to the US market average (8.54x)
P/E vs Market Valuation
COLL is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more COLL due diligence checks available for Premium users.
Valuation
COLL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
15.69x
Industry
-5.68x
Market
8.54x
COLL is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
COLL is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
COLL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.84x
Industry
1.59x
COLL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
COLL price to earnings growth (PEG)
For valuing profitable companies with growth potential
COLL is good value based... subscribe to Premium to read more.
PEG Value Valuation
COLL's financial health
Profit margin
Revenue
$193.5M
Net Income
$14.5M
Profit Margin
7.5%
COLL's Earnings (EBIT) of $185.62M... subscribe to Premium to read more.
Interest Coverage Financials
COLL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.7B
Liabilities
$1.3B
Debt to equity
4.29
COLL's short-term assets ($745.67M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
COLL's long-term liabilities ($904.56M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
COLL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
COLL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$57.1M
Investing
$1.6M
Financing
-$21.3M
COLL's operating cash flow ($331.04M)... subscribe to Premium to read more.
Debt Coverage Financials
COLL vs Pharmaceutical Stocks
Collegium Pharmaceutical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.